Chief Financial Officer

Adam Heikal is a strategic finance and corporate development executive with a proven history of scaling high-growth biotechnology and technology platforms from venture-backed stages through public market exits. Most recently, he served as Head of Finance for a clinical-stage biotech company, effectively operating as the Chief Financial Officer. In this capacity, he designed the financial infrastructure essential for supporting IND-enabling milestones and clinical execution, while concurrently leading multiple financing rounds and spearheading business development initiatives, including a significant strategic collaboration with a global pharmaceutical leader valued in the multi-billions.

Preceding his executive tenure in the biotech sector, Mr. Heikal drove finance and strategic initiatives for several category-defining global platforms. His experience encompasses directing IPOs, managing capital strategy and credit facilities, and leading multiple M&A transactions. Mr. Heikal began his career as an investor in venture and private equity, where he concentrated on growth-stage investments.

Beyond his direct executive responsibilities, Mr. Heikal acts as a strategic advisor to emerging therapeutics companies, offering guidance to leadership teams on financing, capital planning, business development, and financial sustainability. He holds an MBA from The Wharton School and studied at the University of California, Berkeley.